Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Rowan Miller, Alexandra Léary, Clare L. Scott, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1606-1622
Open Access | Times Cited: 361

Showing 1-25 of 361 citing articles:

Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Antonio González‐Martín, Philipp Harter, Alexandra Léary, et al.
Annals of Oncology (2023) Vol. 34, Iss. 10, pp. 833-848
Open Access | Times Cited: 156
Homologous Recombination Deficiency: Concepts, Definitions, and Assays
Mark Stewart, Diana Merino Vega, Rebecca C. Arend, et al.
The Oncologist (2022) Vol. 27, Iss. 3, pp. 167-174
Open Access | Times Cited: 150
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Ignace Vergote, Antonio González‐Martín, Isabelle Ray‐Coquard, et al.
Annals of Oncology (2021) Vol. 33, Iss. 3, pp. 276-287
Open Access | Times Cited: 116
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Esther Schoutrop, Lidia Moyano‐Galceran, Stéphanie Lheureux, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 207-223
Open Access | Times Cited: 90
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Dana Jurkovičová, Christiana M. Neophytou, Ana Čipak Gašparović, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14672-14672
Open Access | Times Cited: 78
PARP Inhibitors in Ovarian Cancer: A Review
David M. O’Malley, Thomas C. Krivak, Nashwa Kabil, et al.
Targeted Oncology (2023) Vol. 18, Iss. 4, pp. 471-503
Open Access | Times Cited: 77
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer
Nitasha Gupta, Tzu‐Ting Huang, Sachi Horibata, et al.
Pharmacological Research (2022) Vol. 178, pp. 106162-106162
Open Access | Times Cited: 75
Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma
Alexandra Lahtinen, Kari Lavikka, Anni Virtanen, et al.
Cancer Cell (2023) Vol. 41, Iss. 6, pp. 1103-1117.e12
Open Access | Times Cited: 53
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 53
What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors
Antonio De Leo, Donatella Santini, Claudio Ceccarelli, et al.
Diagnostics (2021) Vol. 11, Iss. 4, pp. 697-697
Open Access | Times Cited: 92
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
Raffaella Casolino, Salvatore Paiella, Danila Azzolina, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 23, pp. 2617-2631
Open Access | Times Cited: 92
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Michela Chiappa, Federica Guffanti, Francesco Bertoni, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100744-100744
Closed Access | Times Cited: 79
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
Giorgio Valabrega, Giulia Scotto, Valentina Tuninetti, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4203-4203
Open Access | Times Cited: 77
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara, et al.
Cancer Research (2022) Vol. 82, Iss. 8, pp. 1646-1657
Open Access | Times Cited: 64
Homologous Recombination Deficiencies and Hereditary Tumors
Hideki Yamamoto, Akira Hirasawa
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 348-348
Open Access | Times Cited: 63
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Dale W. Garsed, Ahwan Pandey, Sián Fereday, et al.
Nature Genetics (2022) Vol. 54, Iss. 12, pp. 1853-1864
Open Access | Times Cited: 59
Advances in the management of peritoneal malignancies
Vahan Képénékian, Aditi Bhatt, Julien Péron, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 11, pp. 698-718
Closed Access | Times Cited: 55
Therapeutic Targeting of DNA Damage Response in Cancer
Wonyoung Choi, Eun Sook Lee
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1701-1701
Open Access | Times Cited: 53
Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images
Tristan Lazard, Guillaume Bataillon, Peter Naylor, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 12, pp. 100872-100872
Open Access | Times Cited: 49
Homologous Recombination Repair Deficiency: An Overview for Pathologists
Kenneth Doig, Andrew Fellowes, Stephen B. Fox
Modern Pathology (2023) Vol. 36, Iss. 3, pp. 100049-100049
Closed Access | Times Cited: 42
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
Rowan Miller, Karim El-Shakankery, Jung‐Yun Lee
Journal of Gynecologic Oncology (2022) Vol. 33, Iss. 3
Open Access | Times Cited: 39
Targeting the DNA damage response for cancer therapy
Nicola J. Curtin
Biochemical Society Transactions (2023) Vol. 51, Iss. 1, pp. 207-221
Open Access | Times Cited: 35
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
European Journal of Cancer (2023) Vol. 188, pp. 131-139
Closed Access | Times Cited: 25
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
Martina Arcieri, Veronica Tius, Claudia Andreetta, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top